Inspire Medical Systems, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
Inspire Medical Systems, Inc. (INSP) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-08-03
- Inspire Medical Systems, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Inspire Medical Systems, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2026-03-31 was $0.00.
- Inspire Medical Systems, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $0.00.
- Inspire Medical Systems, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-30 was $0.00.
- Inspire Medical Systems, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $4.05M.
- Inspire Medical Systems, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $0.00.
- Inspire Medical Systems, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $0.00 10-Q · filed 2026-08-03 | $0.00 derived: sum of 3 quarters · filed 2026-08-03 | $0.00 derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $0.00 derived: sum of 3 quarters · filed 2026-05-04 | $4.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $0.00 derived: sum of 2 quarters · filed 2026-02-13 | $4.00M derived: sum of 3 quarters · filed 2026-08-03 | $4.05M 10-K · filed 2026-02-13 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 | $4.00M derived: sum of 2 quarters · filed 2026-08-03 | $4.05M 10-Q · filed 2025-11-03 | $4.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $4.00M 10-Q · filed 2026-08-03 | $4.05M 10-Q · filed 2026-08-03 | $4.00M derived: sum of 3 quarters · filed 2026-08-03 | $4.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $0.00 derived: sum of 3 quarters · filed 2026-05-04 | $0.00 derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $0.00 derived: sum of 2 quarters · filed 2026-02-13 | $0.00 derived: sum of 3 quarters · filed 2026-02-13 | $0.00 10-K · filed 2026-02-13 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-04 | $0.00 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-13 | $400.00K 10-K · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |